Abstract
The osteoblast-derived paracrine factor osteoprotegerin (OPG) is considered to play a key role in inhibition of osteoclast formation and activity. Recently, raloxifene, a nonsteroidal benzothiophene, was found to exert anti-resorptive effects via modulating OPG expression in osteoblasts. To explore whether raloxifene regulates bone metabolism via an OPG-dependant pathway in vivo, we investigated the effects of raloxifene on bone loss in Opg-deficient mice. The results show that bone mineral density and bone strength are increased in mice deficient for Opg after treatment with raloxifene for 30 days. Histomorphometric analysis shows that raloxifene can increase bone trabecular area and decrease the number of osteoclasts in Opg −/− mice. Moreover, raloxifene reduces Rankl transcription and serum level of Rankl, which is dramatically increased in Opg knockout mice. These results suggest that raloxifene-induced inhibition of bone resorption may be independent of Opg pathway in mice.
Similar content being viewed by others
References
B.L. Riggs, Overview of osteoporosis. West. J. Med. 154, 63–77 (1991)
Writing Group for the Women’s Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002)
J.V. Lacey Jr., P.J. Mink, J.H. Lubin, M.E. Sherman, R. Troisi, P. Hartge, A. Schatzkin, C. Schairer, Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288, 334–341 (2002)
M.W. Draper, D.E. Flowers, W.J. Huster, J.A. Neild, K.D. Harper, C. Arnaud, A controlled trial of raloxifene (LY139481) HCL, impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11, 835–842 (1996)
B. Fournier, S. Haring, A.M. Kaye, D. Sömjen, Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. J. Endocrinol. 150, 275–285 (1996)
N.N. Yang, M. Venugopalan, S. Hardikar, A. Glasebrook, Identification of an estrogen response element activated by metabolites of estradiol and raloxifene. Science 273, 1222–1225 (1996)
N.K. Shevde, A.C. Bendixen, K.M. Dienger, J.W. Pike, Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-jun repression. Proc. Natl. Acad. Sci. USA 97, 7829–7834 (2000)
M. Sato, M.K. Rippy, H.U. Bryant, Raloxifene, tamoxifene, nofoxidine or estrogen effects on reproductive and non-reproductive tissue in ovariectomized rats. FASEB 10, 905–912 (1996)
L.J. Black, M. Sato, E.R. Rowley et al., Roloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 207, 19–37 (1994)
A. Taranta, M. Brama, A. Teti, V. De Luca, R. Scandurra, G. Spera et al., The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30, 368–376 (2002)
A.C. Ramalho, P. Couttet, C. Baudoin, C. Morieux, A.N. Graulet, M.C. Devernejoul, M.E. Cohen-solal, Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur. Cytokine Netw. 13, 39–45 (2002)
V. Viereck, C. Gründker, S. Blaschke, B. Niederkleine, H. Siggelkow, K.H. Frosch, D. Raddatz, G. Emons, L.C. Hofbauer, Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J. Clin. Endocrinol. Metab. 88, 4206–4213 (2003)
J. Cheung, Y.T. Mak, S. Papaioannou, B.A. Evans, I. Fogelman, G. Hampson, Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J. Endocrinol. 177, 423–433 (2003)
E.M. Messalli, G. Mainini, C. Scaffa, A. Cafiero, P.L. Salzillo, A. Ragucci, L. Cobellis, Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 56, 38–44 (2007)
Y. Xu, H. Yang, J.-O. Qiao, X.-H. Li, L.-Z. Yan, L. Wang, G.-J. Xu, J. Fei, J.-L. Fu, Z.-G. Wang, High-bone-turnover osteoporosis and aortic calcification in Opg knockout mice. Prog. Biochem. Biophys. 34, 260–266 (2007)
A.M. Parfitt, M.K. Drezner, F.H. Glorieux, J.A. Kanis, H. Malluche, P.J. Meunier, S.M. Ott, R.R. Recker, Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595–610 (1987)
N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W.L. Xu, D.L. Lacey, W.J. Boyle, W.S. Simonet, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260–1268 (1998)
E.F. Eriksen, D.S. Colvard, N.J. Berg, M.L. Graham, K.G. Mann, T.C. Spelsberg, B.L. Riggs, Evidence of estrogen receptor in normal human osteoblast-like cells. Science 241, 84–86 (1988)
S. Migliaccio, V.L. Davis, M.K. Gibson, T.K. Gray, K.S. Korach, Estrogens modulate the responsiveness of osteoblast-like cells stably transfected with estrogen receptor. Endocrinology 130, 2617–2624 (1992)
O. Vidal, L.G. Kindblom, C. Ohlsson, Expression and localization of estrogen receptor beta in murine and human bone. J. Bone Miner. Res. 14, 923–929 (1999)
S. Bord, A. Horner, S. Beaven, J. Compston, Estrogen receptors alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86, 2309–2314 (2001)
I.P. Braidman, L. Hainey, G. Batra, P.L. Selby, P.T. Saunders, J.A. Hoyland, Localization of estrogen receptor beta protein expression in adult human bone. J. Bone Miner. Res. 16, 214–220 (2001)
S. Denger, G. Reid, F. Gannon, Expression of the estrogen receptor during differentiation of human osteoclasts. Steroids 73, 765–774 (2008)
V. Mann, C. Huber, G. Kogianni, F. Collins, B. Noble, The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone 40, 674–684 (2007)
W. Gianni, A. Ricci, P. Gazzaniga, M. Brama, M. Pietropaolo, S. Votano, F. Patanè, A.M. Aglianò, G. Spera, V. Marigliano, S. Ammendola, D. Agnusdei, S. Migliaccio, R. Scandurra, Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J. Clin. Endocrinol. Metab. 89, 6097–6099 (2004)
Acknowledgment
This work was partially supported by the grant of Science and Technology Commission of Shanghai Municipality (06ZR14139, 09GC1410300).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yan, Mz., Xu, Y., Gong, Yx. et al. Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism. Endocr 37, 55–61 (2010). https://doi.org/10.1007/s12020-009-9267-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-009-9267-y